Adaptimmune – engineered, increased affinity T cell receptors

Adaptimmune is focused on T cells to target and destroy cancer by using engineered, increased affinity T cell receptors (TCRs) as a means of strengthening natural patient T cell responses.

Adaptimmune – engineered, increased affinity T cell receptors

adaptimmune Continue reading

Immunocore – T cell receptor-based drugs

Immunocore is a clinical-stage biotech company focused on the development of novel T cell receptor-based drugs to treat cancers and viral diseases. Immunocore is the world-leader in engineering T Cell Receptors (TCRs) and link them to an antibody fragment (scFv). Its first product candidate, IMCgp100, entered clinical trials in patients with metastatic melanoma.

Immunocore – T cell receptor-based drugs

Immunocore

Continue reading